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ages mentioned below were not measured with this instrument due to lack of hands
on experience by the author. TreeAge ProSuite was included as a gold standard com-
parator forHE. A Linkert scale (1 to 5)was used to grade each item.RESULTS: Thirteen
packages were found and considered in this review. Among the best software (in-
cluded two or three characteristics of the selection criteria) suitable for HE modeling
were AnyLogic, Arena, SAS Simulation Studio, Simio, Simul8 and TreeAge. Average
grades (ordered from less expensive tomost expensive)were as follows: Simul8-Basic,
3.89; TreeAge ProSuite, 3.07; Arena-Basic, 3.00; Simul8-Professional, 4.43.
CONCLUSIONS: This work tried to create a list of items to objectively measure the
characteristics of HE modeling software. At this point results of the graded packages
represent theviewsof theauthor. This instrumentmaybeauseful toolwhendeciding
between different packages to buy. Future work is required for this instrument to be
assessed by other modeling experts.
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VALIDATING AN ONLINE CALCULATOR FOR EVALUATING HEALTH
INTERVENTION OPTIONS USING THE ANALYTIC HIERARCHY PROCESS (AHP)
McGhan WF, Vichaichanakul K, Willey VJ
University of the Sciences, Philadelphia, PA, USA
OBJECTIVES: To evaluate an online calculator for analyzing and scoring health
intervention options using the analytic hierarchy process (AHP).METHODS:Aweb-
based calculator was developed that generates priority scores using the Analytic
Hierarchy Process as well as various AHP statistics and graphs. AHP is designed to
assist in decision-making situations involving multiple attributes by making judg-
ments about the relative importance of key attributes and then specifying a pref-
erence for each decision alternative on each attribute. The web-based software is
freely available at: www.healthstrategy.com (HDS). The tool was compared to an
MS Excel calculator from K. Teknomo which can be downloaded from: http://peo-
ple.revoledu.com/kardi/tutorial/AHP. These two software options were evaluated
against results from a published health economics paper from Nuijten and Kosa
that utilized AHP on three antidepressant choices around the threemain factors of
budget impact, therapeutic value, and cost effectiveness. RESULTS: The published
paper results compared with the Teknomo and HDS calculators were as follows on
factor weights: Budget Impact (0.28, 0.28, 0.28), Cost Effectiveness (0.07, 0.07, 0.07),
Therapeutic Value (0.65, 0.64, 0.64). On overall score (composite weights) the pub-
lished paper compared with the Teknomo and HDS calculators as follows: New
Drug (0.49, 0.56, 0.56), SSRI (0.26, 0.18, 0.18), TCA (0.25, 0.26, 0.26). CONCLUSIONS:
Both software approaches provided basic statistics and graphs often found in AHP
reports. For basic scoring, the HealthStrategy and Teknomo approaches provided
similar results, but differed somewhat from the published paper that used addi-
tional sub-factors on some attributes. For future research, additional datasets
should be explored, sensitivity analyses should be performed on key variables, and
comparisons should be made with more comprehensive software and multi-attri-
bute utility approaches.
Research on Methods – Patient-Reported Outcomes Studies
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ADHERENCE IS ADHERENCE IS ADHERENCE: THE CONSISTENCY OF MORISKY
ADHERENCE SCORES ACROSS THE COSTLIEST CHRONIC CONDITIONS
DiBonaventura MD1, Annunziata K2, Goren A1, Gupta S2
1Kantar Health, New York, NY, USA, 2Kantar Health, Princeton, NJ, USA
OBJECTIVES: Patient non-adherence to prescribed therapies has been shown to be
associated with worse health outcomes. However, it is unclear the extent to which
adherence varies as a function of the condition versus the patient. The aim of this
study was to investigate the consistency of adherence scores across the costliest
chronic conditions in the U.S.METHODS: Data from the 2010 U.S. National Health
and Wellness Survey (NHWS) were used. Included for analysis were only those
patients (N32,636) who reported using a medication for their asthma, pain, con-
gestive heart failure (CHF), COPD, diabetes, hypertension, depression, bipolar dis-
order, peripheral vascular disease (PVD), transient ischemic attack (TIA), or stroke.
Adherence, measured using the four-item Morisky Medication Adherence Scale
(MMAS), was assessed separately for each condition. Health utilities were also
assessed using the SF-12v2. RESULTS: Among patients taking prescription medi-
cation for asthma (n4,786), pain (n8,984), CHF (n905), COPD (n1,664), diabetes
(n7,065), hypertension (n19,475), depression (n7,850), bipolar disorder
(n1,425), PVD (n163), TIA (n437), or stroke (n507), 48.9% were male, 79.3%
were white, and mean age was 54.9 years (SD15.3). Across all conditions, high
internal consistency was observed for total MMAS scores (Cronbach’s a0.97) and
all MMAS items (“careless about taking medications”, a0.97; “stop taking medi-
cations when feeling better”, a0.94; “stop taking medications when feeling
worse”, a0.96; and “forgetting to take medications”, a0.97). Number of respon-
dents sharing any two conditions ranged from n9 to n4563, yet MMAS total
score correlations across any two conditions were all significant, ranging from
r0.41 to r1.00.With the exception of pain, non-adherencewithin each condition
was associated with lower health utilities (though not always significantly:
r0.02 to r0.12).CONCLUSIONS: The results suggest that adherence is a stable
construct, consistent from condition to condition for each patient. Non-adherence
on one therapy may be an indicator of non-adherence on another therapy.
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VALIDATION AND PSYCHOMETRIC EVALUATION OF A 5-ITEM MEASURE OF
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OBJECTIVES: Previous researchers (Ren, 1999) have used a 5-item shortened ver-
sion of the Medical Outcomes Study Social Support Scale (MOS-SSS; Sherborne,
1991), but the measurement properties of this brief measure have not been estab-
lished. We filled this gap by evaluating the psychometric properties of a 5-item
perceived social support instrument (the SS-5) and testing equivalence between
paper and web-based administration modes.METHODS: The SS-5 and other ques-
tionnaire measures were administered to a sample of adults recruited through
newspaper and web-based advertisements in 8 US cities. Participants were ran-
domized to complete the SS-5 on either paper or computerized format followed by
a one-week retest. The intraclass correlation coefficient (ICC) was calculated to
assess reproducibility of the SS-5 and equivalence between administrationmodes.
Cronbach’s alpha was calculated to assess internal consistency. To assess known
groups’ validity, differences in SS-5 scores between marital status/living arrange-
ment groups and (separately), trichotomous groupings of a validated measure of
dispositional optimism, the Life Orientation Test (LOT-R), were assessedwith anal-
ysis of variance (ANOVA)models. RESULTS:Of the 258 participants that completed
the baseline assessment, 251 (97%) completed the retest. Mean age of participants
was 48.6 years, 61% were female, and 71% were Caucasian. Participants included
44% married or living with a partner; 24% had never been married. The mean SS-5
scorewas 17.34.9, and the ICC between paper andweb-basedwas 0.89. Reproduc-
ibility was strong (ICC0.92), and the instrument was internally consistent (al-
pha0.88). The SS-5 significantly discriminated between participants living with a
partner and those living alone (means: 19.1 vs. 15.9; p0.001) and tertiles of the
LOT-R. The correlation of SS-5 scores to the full MOS-SSS was 0.91. CONCLUSIONS:
The SS-5 was observed to have adequate reproducibility and internal consistency;
and demonstrated appropriate known groups validity. Equivalence between paper
and web-based administration was demonstrated.
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DEVELOPMENT AND VALIDATION OF A HEALTH RELATED QUALITY OF LIFE
INSTRUMENT TO MEASURE THE IMPACT OF OVER-THE-COUNTER PRODUCT
USE AND ASSOCIATED ADVERSE EVENTS
Chopra P, Patel H, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: A self-administered questionnaire was developed to evaluate health
related quality of life (HRQoL) with over-the-counter (OTC) product use and HRQL
with OTC product use associated adverse drug events (ADRs). Validity and reliabil-
ity was assessed to determine psychometric properties of these new instruments.
METHODS: The questionnaire was developed as part of a cross sectional study in
an elderly population and included content based on existing literature and dis-
cussionswith expert panel. HRQoLOTC product use scale (9 items) andHRQoLOTC
ADR scale (9 items) was measured using a 5-point Likert scale (strongly agree to
strongly disagree). The questionnaire was tested on a pilot sample to evaluate
legibility, response burden, and comprehension. Seniors residing in retirement
homes or visiting senior community centers and using OTC products participated.
Reliability was evaluated on the basis of internal consistency. Concurrent validity
was evaluated by comparing scores obtainedwith an existing general health status
measure (GHS). Data were collected and analyzed using SAS v9.2. RESULTS: A total
of 157 seniors completed the survey yielding a response rate of 66.5%. The mean
age of the sample was 75.1(4.7) years with majority being male (56.2%) and white
(67.5%). Of the total sample, 22.9% had an adverse event due to OTC use. The
reliability coefficient was very high for the two scales, namely, HRQL OTC product
use scale (0.95) and HRQoL OTC ADR scale (0.92), with mean summary scores of
3.60.8 and 2.50.6, respectively. The GHS measure was significantly correlated
with HRQoL OTC product use (r0.3, p0.0001) and HRQoL OTC ADR (r 0.5,
p0.01) scores. In addition, both scales were significantly correlated with each
other (r0.7, p0.0001). CONCLUSIONS: Both scales exhibit excellent reliability
and evidence of validity. Further, assessment using other products and different
populations would help increase generalizability of these instruments.
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OBJECTIVES: There is some debate about whether utilities can exceed 1.0. This
assumption has important ramifications regarding which statistical methods are
appropriate. It is convention that utilities are anchored at 0.0 (death) and 1.0 (full
health). The descriptive health state corresponding to ‘full health’ differs across
instruments. The objective of this research is to examine the extent to which the
value for ‘full health’ differs between the SF-6D and the EQ-5D and to explore the
existence of a ceiling effect for utilities.METHODS: The 2000-2003 Medical Expen-
diture Panel Survey was used to estimate predicted SF-6D and EQ-5D (UK) scores
using Tobit, CLADandOLS regressions. EQ-5D (and SF-6D) scoreswere regressed on
SF-12 scores and sociodemographic characteristics. The regression equationswere
then used to predict EQ-5D and SF-6D scores. The two series of predicted scores
were compared to examine ceiling and floor effects. RESULTS: 47% of individuals
had a score of 1.0 on the EQ-5D and only 7% on the SF-6D. The SF-6D exhibited
significant floor effects with the lowest value at 0.344 compared to 0.594 for the
EQ-5D. Based on the Tobit predicted scores, a value of 1.0 on the SF-6D corre-
sponded to a value of 1.2 on the EQ-5D. This result suggests that a large portion of
the 46% of individuals with a score of 1.0 on the EQ-5D would actually have utility
scores greater than 1.0 on a scale without such a pronounced ceiling effect. Like-
wise a 0.34 on the SF-6D corresponded to 0.03 on the EQ-5D, suggesting a floor effect
for the SF-6D. CONCLUSIONS: Statistical estimation should incorporate censored
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regression methods to address ceiling and floor effects evident both theoretically
and empirically. Also, future descriptive systems and tariff valuation processes
should incorporate values that exceed ‘full health’ (1.0) as is currently done for
‘death’ (0.0).
PRM19
NON-RESPONSE BIAS IN A SURVEY ASSESSING PATIENTS’ MEDICATION AND
HEALTH BELIEFS
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OBJECTIVES: The objectives of this study were to investigate whether medication
adherence and persistence differed across: (1) responders vs. non-responders; and
(2) early vs. late responders to a survey assessing medication and health beliefs.
METHODS: A survey assessing medication and health beliefs was mailed to pa-
tientswho filled a qualifying index prescription for one of five chronic conditions at
one national and two regional retail pharmacies in 2008. Adherence and persis-
tence to the index drug class was measured using pharmacy claims data over 12
months. A multivariate generalized linear model with a negative binomial distri-
bution and log-link function was used to determine the significant predictors of
adherence. Kaplan-Meier estimates of survival (persistence) curves were used to
assess the time to discontinuation, and the multivariate Cox proportional hazards
model was used to identify significant predictors of non-persistence. To assess
differences between early vs. late responders, medication beliefs were compared
across timing quartiles based on survey response time (date signed minus date
mailed). RESULTS: A final survey response rate of 24.25% was achieved. Survey
non-responders had statistically significantly lower medication adherence than
responders. As assessed by the log-rank test, the Kaplan-Meier estimate of the
persistence curve for responders was statistically significantly higher (indicating
better persistence) than the one for non-responders These results were confirmed
by the multivariate Cox proportional hazards model for time-to-discontinuation
outcome. Compared to early survey responders, late responders reported less per-
ceived need (p.003), more medication concerns (p.031), less prescription-medi-
cation knowledge (p.008), and less trust in their prescribing physician (p.002).
CONCLUSIONS:Our study found evidence of non-response bias in a survey assess-
ing patients’medication andhealth beliefs. Non-response bias by adherence status
can result in biased estimates ofmedication beliefs.We recommendusingmultiple
survey levers to increase response rate among non-adherent patients to reduce the
potential for non-response bias.
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OBJECTIVES: To identify trends in the use of direct and indirect utility elicitation
techniques in published cost-effectiveness analyses.METHODS:We analyzed data
extracted from cost-effectiveness analyses (CEAs) included in the Tufts Medical
Center Cost-effectiveness Analysis Registry, a database with detailed information
on CEAs published in the peer-reviewed medical and economic literatures. Using
studies from 1991-2008, we analyzed the proportion of utilityweights elicited using
direct vs. indirect methods, type of direct or indirect elicitation method, source of
weights, age of the population affected by the disease, and disease category.
RESULTS: For CEAs published from1991 to 2008, 42%of utilityweightswere elicited
using direct elicitation methods, 35% using indirect methods, and methods were
not reported for 23%. During this time, the proportion of direct and indirect re-
mained similar. For direct methods in adults, the rating scale remainedmost com-
mon (25% for ‘91-‘93 and ‘06-‘08). For direct methods in child health, author/clini-
cian judgment was most common in earlier years (91%) compared with the
standard gamble later (31%). For indirect methods, the most common method in
recent years was the EQ-5D for adults and the HUI for children. Trends in the
identified source of utility weights demonstrated an increase in patient or commu-
nity members as the source accompanied by a decline in clinicians or authors as
the source. Specific characteristics of utility weights were missing for 6-60% of
utility weights depending on the year. CONCLUSIONS: Trends over time show
increasing adherence to guideline recommendations. A substantial proportion of
CEAs using direct elicitation methods in recent years suggests there may be a
continued role for direct elicitation for certain populations or types of health. The
high proportion of studies lacking details for health utilities suggests greater at-
tention needs to be paid toward providing transparency in utility weights for pub-
lished cost-effectiveness analyses.
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CONVERTING PAPER VERSIONS OF PATIENT REPORTED OUTCOME
INSTRUMENTS TO ELECTRONIC VERSIONS: IDENTIFYING THE REQUIRED STEPS
Ross J1, O’Gorman HJ2, Peck R1, Ross E1
1Almac Clinical Technologies, Souderton, PA, USA, 2Almac Group, Craigavon, UK
OBJECTIVES: Electronic Patient Reported Outcomes (ePRO) is a growing to be a
preferred selection for collection of Patient Reported Outcomes (PRO) data. How-
ever, there are a number of PRO instruments that are only available in paper ver-
sion. Researchers may be unaware of steps required for converting paper to elec-
tronic versions and that different steps may be required pending on level of
modification involved. This presentation intends to provide guidance for identify-
ing required steps in converting paper to ePRO and to identify FDA’s PRO Guidance
as a resource.METHODS: Required actions can be determined with input from the
following: original author, psychometrician, FDA reviewer, etc. It is the Research-
er’s responsibility to determine the action plan on received input. Actions to dem-
onstrate measurement equivalence include: clinical reviews, cognitive debriefs,
usability testing, equivalence testing and full psychometric testing. Since the de-
cision is determined based on the magnitude of modification, it is important to
distinguish each level of modification. This session will provide examples with
application of FDA’s PRO guidance. RESULTS: Examples: Small – modifications
such as changing wording from ”circle yes/no” to ”press 1 for yes, press 2 for no”;
clinical review, small scale cognitive and usability testing would likely be recom-
mended. Medium – modifications such as changing sentence structure or format;
clinical review, cognitive debrief, and some usability testing would likely be re-
quired. Large – modifications such as removing items or scale anchors, changing
question wording; a full validation study and large scale usability testing would
likely be necessary. CONCLUSIONS: Classification of level of modification is based
on the potential effect on the original version’s meaning. Demonstration that the
modified version has either equivalent or superior psychometric properties in re-
spect to the original version is important, as failure to do so may result in serious
consequences for trials where the modified version is used.
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STAGES OF NON-PERSISTENCE: A NOVEL WAY OF FRAMING LONGITUDINAL
PERSISTENCE TO CHRONIC MEDICATIONS
Gadkari A, McHorney C
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OBJECTIVES: The objective of this study is to propose and provide preliminary
evidence of validity of a novel, staging approach for framing longitudinal persis-
tence to chronic medications. METHODS: A survey assessing medication and
health beliefs was mailed to patients with one of five chronic conditions in 2008.
Multi-item scales assessed perceived need for medications (k8), side-effect con-
cerns (k5), perceived medication affordability (k4), perceived disease severity
(k4), trust in physician (k2), medication-safety concerns (k3), and perceived
value of prescription medications (k1). Persistence over 14 months was assessed
using the continuous measure of medication gaps (CMG) from pharmacy claims
data. Patients were categorized in one of the following six mutually-exclusive cat-
egories: (1) non-persistent after first fill; (2) non-persistent after second fill; (3)
non-persistent after third fill; (4) non-persistent after fourth or subsequent fill; (5)
persistent across 14 months but with gaps in therapy; and (6) persistent across 14
months with no gaps in therapy. Mean scores for the belief scales were compared
across the six stages, and multivariate regression models were used to assess
whether scores differed significantly across stages. RESULTS: Mean scores for all
belief scales generally showed a linear, monotonic increase across the six stages.
Percent difference between the first and last stage ranged from a low of 7.5% for
trust in physician scale to a high of 24.2% for perceived value of prescription med-
ications. Multivariate analyses found significant differences in scale scores across
the stages for all seven scales (p0.001). CONCLUSIONS: Our results provide pre-
liminary validation of a novel approach to frame longitudinal persistence to
chronic medications. This study demonstrates that patients’ beliefs may help pre-
dict not onlywhether they discontinue therapy but alsowhen theymay discontinue
the prescribed therapy. Improving medication beliefs may help to move patients
gradually along the continuum from early non-persistence to perfect adherence.
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MEASURING THE IMPACT OF PREVIOUS TREATMENT CYCLES ON HEALTH
UTILITY IN PATIENTS RECEIVING BOTULINUM TOXIN TYPE A (BONTA) IN A
PROSPECTIVE OBSERVATIONAL COHORT STUDY: MOBILITY STUDY
Simonyi S1, Jog M2, Wein T3, Beauchamp R4, Miller R5, Ismail F6, Bhogal M1, Huang B7
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OBJECTIVES: Health utility may improve over time after initiation of BoNTA treat-
ment as injection dose and location are optimized leading to a steady state. The
BOTOX Exposure Index (BEI) was developed to model the longitudinal effect of
previous BoNTA exposure on health utility.METHODS: The MOBILITY study mea-
sures health utility via the SF-6D in naïve and previously-treated (maintenance)
patients receiving BoNTA for various indications, including spasticity, hyperhidro-
sis, and dystonias. Treatment history, SF-12v2 Physical (PCS) and Mental (MCS)
Component Summary scores, and SF-6Dwere reported. The BEIwasmodeled using
interim study data from 795 patients. The BEI of a patient treated with dose (d)
units/treatment and number (n) of previous treatment cycles is: BEIn●d●f(x;)dx
integral tf to tl where tf and tl are the time (yrs) from the first and last injections
before baseline and  is the shape parameter that characterizes the expected du-
ration of time that the treatment effect remains. The BEI was then standardized to
reduce variation across indications. RESULTS: Logarithmic transformation of the
BEI resulted in a more normalized distribution of BoNTA exposure, and allowed
categorization into low (0.5 standard deviations (SD) from themean exposure),
moderate (0.5 – 0.5 SD), and high ( 0.5 SD) BEI. Among 285 naïve patients, the BEI
was significantly associatedwith the change in SF-6D (p0.004), PCS (p0.007), and
MCS (p0.046). Among maintenance patients with a low (n205), moderate
(n285) or high BEI (n181), improvements in SF-6D were associated with moder-
ate BEI (p0.020) and improvements in MCS with low BEI (p0.021).
CONCLUSIONS: The BEI is associated with improvement in PCS, MCS and SF-6D
scores in naïve patients, and improvement in selected scores in the maintenance
population. Overall, the BEI model suggests health utility improves in naïve pa-
tients, whereas patients on an established treatment regimen are more likely to
sustain their existing SF-6D and component scores.
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